Overview Alfentanil: Simultaneous Testing Pilot Status: Completed Trial end date: 2016-09-01 Target enrollment: Participant gender: Summary To evaluate two paradigms for simultaneous assessment of hepatic and intestinal CYP3A activity. Phase: N/A Details Lead Sponsor: Washington University School of MedicineCollaborator: National Institute of General Medical Sciences (NIGMS)Treatments: AlfentanilKetoconazoleRifampin